P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Proteasome inhibition for the treatment of glioblastoma.
TL;DR: Marizomib is a novel drug that displays strong inhibitory properties on all enzymatic subunits of the proteasome and crosses the blood-brain barrier, making it a potentially very active novel agent against intrinsic brain tumors.
Journal ArticleDOI
A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
David S. Siegel,Donna M. Weber,Constantine S. Mitsiades,Syed Rizvi,Jose Garcia-Vargas,Jason Howe,David Reiser,Kenneth C. Anderson,Paul G. Richardson +8 more
TL;DR: Vorinostat with lenalidomide and dexamethasone represents a novel combination therapy for the treatment of relapsed or relapsed, refractory MM, and preliminary results suggest that the combination is well tolerated to date, is active and has the convenience of oral administration.
Journal ArticleDOI
Comfort care in burns: The Burn Modified Liverpool Care Pathway (BM-LCP)
S. J. Hemington-Gorse,A.J.P. Clover,C. MacDonald,J. Harriott,Paul G. Richardson,Bruce Philp,Odhran Shelley,Peter Dziewulski +7 more
TL;DR: The BM-LCP appears to be an appropriate tool for assisting in end of life care in burns and when used appears to improve end oflife care.
Journal ArticleDOI
Characterization of Specific N-α-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library
Pei-Pei Kung,Patrick Bingham,Benjamin J. Burke,Chen Qiuxia,Xuemin Cheng,Ya-Li Deng,Dou Dengfeng,Junli Feng,Gary M. Gallego,Michael R. Gehring,Stephan Grant,Samantha Elizabeth Greasley,Anthony R. Harris,Karen A. Maegley,Jordan L. Meier,Xiaoyun Meng,Jose L Montano,Barry A. Morgan,Brigitte S Naughton,Prakash B. Palde,Thomas A Paul,Paul G. Richardson,Sylvie K. Sakata,Alex Shaginian,William K Sonnenburg,Chakrapani Subramanyam,Sergei Timofeevski,Jinqiao Wan,Wen Yan,A.E. Stewart +29 more
TL;DR: Biophysical and biochemical data as well as cocrystal structures were obtained for both compounds and these data were used to rationalize the binding affinity differences observed between the two compounds and a MLGP peptide-containing substrate and confirm the Naa50 binding of 4a.
Journal ArticleDOI
Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.
Paul G. Richardson,Vania Hungria,Sung-Soo Yoon,Meral Beksac,Meletios A. Dimopoulos,Ashraf Elghandour,Wiesław Wiktor Jędrzejczak,Andreas Guenther,Thanyaphong Na Nakorn,Noppadol Siritanaratkul,Robert L. Schlossman,Jian Hou,Philippe Moreau,Sagar Lonial,Jae Hoon Lee,Hermann Einsele,Monika Sopala,Bourras-Rezki Bengoudifa,Claudia Corrado,Jesús F. San-Miguel +19 more
TL;DR: The primary endpoint was progression free survival (PFS) with response assessed by modified EBMT criteria, and other endpoints included overall survival (OS), overall response rate (ORR), near complete/complete res...